Crossmark

Endocan as a marker of endotheliitis in COVID-19 patients: modulation by veno-venous extracorporeal membrane oxygenation, arterial hypertension and previous treatment with renin–angiotensin–aldosterone system inhibitors

Crossref DOI link: https://doi.org/10.1007/s00011-024-01964-8

Published Online: 2025-01-25

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Reina-Couto, Marta

Alves, David

Silva-Pereira, Carolina

Pereira-Terra, Patrícia

Martins, Sandra

Bessa, João

Teixeira-Santos, Luísa

Pinho, Dora

Morato, Manuela

Dias, Cláudia Camila

Sarmento, António

Tavares, Margarida

Guimarães, João T.

Roncon-Albuquerque, Roberto

Paiva, José-Artur

Albino-Teixeira, António

Sousa, Teresa
Funding

Funding for this research was provided by:

Universidade do Porto
License Information

Text and Data Mining valid from 2025-01-25

Version of Record valid from 2025-01-25
More Information

Article History

Received: 30 October 2024

Revised: 30 October 2024

Accepted: 16 December 2024

First Online: 25 January 2025

Declarations

:

: The authors declare no competing interests.

: The CHUSJ Health Ethics Committee approved this study [CES 75-16], with project amended specifically for inclusion of subjects with COVID-19, within the scope of a RESEARCH 4 COVID-19 grant from FCT (special support for rapid implementation projects for innovative response solutions to COVID-19 pandemic)]. All eligible patients provided written informed consent to participate in the study. For ICU patients unable to give consent, this was solicited to their next of kin. These patients provided informed consent retrospectively, where possible. Blood donor volunteers provided oral informed consent.

: All authors agree to publish this article.

Document is current

Any future updates will be listed below